Improving the efficacy of cancer immunotherapy
Authors:
- A.G. DalgleishADA.G. Dalgleish
- C.M. BrittenCBC.M. Britten
- L.H. FinkeLFL.H. Finke
- G. GaudernackGGG. Gaudernack
- S. GnjaticSGS. Gnjatic
- K. KallenKKK. Kallen
- R. KiesslingRKR. Kiessling
- M. Schuessler-LenzMSM. Schuessler-Lenz
- H. SinghHSH. Singh
- J. TalmadgeJTJ. Talmadge
- H. ZwierzinaHZH. Zwierzina
- 1 May 2009
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (8) , 1424-1431
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Understanding intravesical BCG: A window to the future treatment of noninvasive bladder cancerUrologic Oncology: Seminars and Original Investigations, 2008
- Lessons from randomized phase III studies with active cancer immunotherapies – Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)Vaccine, 2007
- Incidence of Malignancies in Heart and/or Lung Transplant Recipients: A Single-Institution ExperienceThe Journal of Heart and Lung Transplantation, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Part II: Vaccines for haematological malignant disordersThe Lancet Oncology, 2004
- Part I: Vaccines for solid tumoursThe Lancet Oncology, 2004
- SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III resultsAnnals of Oncology, 2004
- A Randomized Pilot Study of SRL172 (Mycobacterium vaccae) in Patients with Small Cell Lung Cancer (SCLC) Treated with ChemotherapyClinical Oncology, 2002
- Tumor antigens recognized by T cellsImmunology Today, 1997
- Tumor Antigens Recognized by T LymphocytesAnnual Review of Immunology, 1994